Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Saniona (Q3 Review) - Gearing up for clinical development

Saniona

Redeye provides an update on Saniona. In Q3, Saniona expectedly received the USD42.5m upfront payment from Jazz Pharmaceuticals. What stood out in the report were the higher costs than expected. These costs were driven by increased headcount, preparations for clinical studies, and a one-off expense related to the Jazz deal. We have increased our cost estimates for primarily 2026-2028e. However, this negative impact is offset by a stronger dollar compared to our last update, leading us to reaffirm our valuation range of SEK7-35, with a base case of SEK19.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Saniona (Q3 Review) - Gearing up for clinical development

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.